Skip to main content
Equibles

TAK · Takeda Pharmaceutical Co Ltd · Metrics

Track TAK — free

Use TAK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TAK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.76 +0.09 (+0.46%)
Rebalance outlook locked
Market Cap
$62.84B
Shares
3.19B
Volume · Oct 16 2.83M Avg daily vol (3M) 2.97M

TAK metrics

81 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.67
Market cap
$62.84B

Price action

20 metrics
Price change (1W)
+5.0%
Price change (30D)
+4.1%
Price change (3M)
+14.7%
Price change (6M)
+10.4%
Price change (YTD)
+26.2%
Price change (1Y)
+41.7%
Trailing year
Price change (5Y)
+39.5%
52-week high
$19.67
52-week low
$13.23
Change from 52-week high
+0.0%
Change from 52-week low
+48.7%
Annualized volatility
21.3%
Annualized volatility (3M)
21.9%
Beta
0.2
RSI (14D)
69.3
Price vs SMA 50
+7.3%
Price vs SMA 200
+13.4%
Avg volume (3M)
2.97M
Relative volume
1.0
Average dollar volume
$53.28M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
3.19B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.0×
reciprocal yield 33.1%
EV / EBITDA
19.1×
reciprocal yield 5.2%
EV / EBIT
516.6×
reciprocal yield 0.2%
P / sales
2.1×
reciprocal yield 47.6%
P / book
1.4
reciprocal yield 74.0%
FCF yield
8.1%
TTM · current market cap
Buyback yield
0.0%
P / FCF
12.4
reciprocal yield 8.1%
P / operating cash flow
10.0
reciprocal yield 10.0%
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
1.6%
Trailing 12 months
Payout ratio
—
Shareholder yield
3.2%
Dividend / share (TTM)
$0.31
Dividend growth YoY
-53.4%
Dividend growth streak
1
Last ex-dividend
2026-03-31

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
66.5%
Operating margin
0.1%
Trailing 12 months
Net margin
-3.4%
Gross profit (TTM)
$3.07T
Operating profit (TTM)
$23.07B
Net income (TTM)
−$1.05B
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1,516.11

Growth

11 metrics
Revenue growth YoY
+10.2%
Year over year
Net income growth YoY
-8.9%
Revenue (TTM)
$29.91B
Trailing 12 months
EPS growth YoY
-9.8%
Shares change YoY
-0.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+3.8%
Revenue CAGR (5Y)
+7.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+1.1%
FCF CAGR (5Y)
-0.8%

Quality

14 metrics
Return on equity
-2.2%
Return on assets
-1.0%
Debt / equity
0.7
Current ratio
1.1
EBITDA (TTM)
$4.73B
Free cash flow (TTM)
$5.09B
Quick ratio
0.6
Interest coverage
—
Net debt / EBITDA
6.2
Return on invested capital
—
Trailing 12 months
Net cash
−$27.54B
Latest balance sheet
Cash & equivalents
$2.83B
Total assets
$96.32B
Total debt
$30.38B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$6.26B
Capital expenditures (TTM)
$1.18B
R&D (TTM)
$4.23B
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
14.1%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
382
13F filer change QoQ
+18
Institutional ownership
3.3%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
35 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$13.09M
Insider-sentiment score
15 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1395064 CUSIP 874060205 13F (30d) 59 filings 44 filers Visit website Investor relations